Anti-Inflammatory Β· ImmuneTier 3 β Animal + early human data
LL-37
Cathelicidin Β· CAMP peptide Β· hCAP18
Human host-defence peptide with broad antimicrobial, immunomodulatory, and wound-healing properties. Deficiency linked to increased susceptibility to infections and inflammatory conditions.
π Topical / SC injectionπ§ Refrigerate; topical formulation: follow compounding pharmacy storage instructions
Want a personalised protocol?
Our AI generator builds a protocol tailored to your profile and goals.
Mechanism of Action
Disrupts bacterial membranes, modulates TLR signalling to reduce excessive inflammation, promotes wound healing via EGFR and FPRL1 activation, and stimulates angiogenesis.
Clinical Applications
- βChronic wound treatment (topical)
- βAntimicrobial defence support
- βCOPD and respiratory tract defence
- βRosacea and inflammatory skin conditions
- βImmune system fortification in deficient states
Dosing Protocol
Recommended Dosing
Topical or SC. Topical: applied directly to wound/skin 1β2x daily. SC: 100 mcg once daily for systemic immune support. Research compound β no standardised protocol.Safety & Contraindications
Possible Side Effects
- β Topical: mild stinging, erythema
- β SC: injection site reactions
- β Potential pro-inflammatory effect at high doses
Contraindications
- βActive malignancy (promotes angiogenesis)
- βPregnancy
Combinations & Synergies
π BPC-157wound healing synergy
π KPVcomplementary anti-inflammatory for skin conditions